Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
TuHURA Biosciences, Inc.
Eli Lilly and Company
M.D. Anderson Cancer Center
BioNTech SE
Astellas Pharma Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Ascendis Pharma A/S
Pfizer
Eikon Therapeutics
Rutgers, The State University of New Jersey
ModernaTX, Inc.
Verastem, Inc.
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca
M.D. Anderson Cancer Center
Eli Lilly and Company
Erasca, Inc.
Eli Lilly and Company
Novartis
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Mayo Clinic
Shenzhen Ionova Life Sciences Co., Ltd.
GI Innovation, Inc.
Eli Lilly and Company
PMV Pharmaceuticals, Inc
Mayo Clinic
Merck Sharp & Dohme LLC
Imugene Limited
Novartis
Ascendis Pharma A/S
Tizona Therapeutics, Inc
Essen Biotech
University of California, San Diego
University of Iowa
Werewolf Therapeutics, Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Wake Forest University Health Sciences
Prelude Therapeutics
University of Oklahoma
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
University of California, San Diego
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Riboscience, LLC.
Sairopa B.V.